Literature DB >> 15028267

Synthesis and biological activity of 2-alkylated deoxyadenosine bisphosphate derivatives as P2Y(1) receptor antagonists.

Romain Mathieu1, Anthony Baurand, Martine Schmitt, Christian Gachet, Jean-Jacques Bourguignon.   

Abstract

A previous study around adenine nucleotides afforded the reference N(6)-methyl-2'-deoxyadenosine-3',5'-bisphosphate (1a, MRS 2179) as a selective human P2Y(1) receptor antagonist (pA(2)=6.55+/-0.05) with antithrombotic properties. In the present paper, we have synthesized and tested in vitro various 2-substituted derivatives with the goal of exploring the 2-position binding region and developing more potent P2Y(1) receptor antagonists. Thus, we have adopted a novel and versatile chemical pathway using a palladium-catalyzed cross-coupling reaction with the 2-iodinated derivative 7 as a common intermediate for a very efficient synthesis of the 2-alkyl-N(6)-methyl-2'-deoxyadenosine-3',5'-bisphosphate nucleotides 1e-i. The biological activity was evaluated through the ability of compounds to inhibit ADP-induced platelet aggregation, intracellular calcium rise and to displace the specific binding of [(33)P]2-MeSADP. 2-Ethyl and 2-propyl groups appeared to be tolerated, whereas a bulky group or a C(3) linear substituent dramatically decreased potency of antagonists. The 2-ethynyl derivative 1h (pA(2)=7.54+/-0.10) was significantly more potent (10-fold) as an antagonist when compared to the reference 1a, revealing a potential electronic interaction highly favorable between triple bond orbitals and the P2Y(1) receptor at this position.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15028267     DOI: 10.1016/j.bmc.2003.12.041

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

Review 1.  International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors:  Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

2.  Pharmacochemistry of the platelet purinergic receptors.

Authors:  Kenneth A Jacobson; Francesca Deflorian; Shilpi Mishra; Stefano Costanzi
Journal:  Purinergic Signal       Date:  2011-02-18       Impact factor: 3.765

Review 3.  Molecular recognition at adenine nucleotide (P2) receptors in platelets.

Authors:  Kenneth A Jacobson; Liaman Mamedova; Bhalchandra V Joshi; Pedro Besada; Stefano Costanzi
Journal:  Semin Thromb Hemost       Date:  2005-04       Impact factor: 4.180

4.  Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.

Authors:  Thomas Gremmel; Ivan B Yanachkov; Milka I Yanachkova; George E Wright; Joseph Wider; Vishnu V R Undyala; Alan D Michelson; Andrew L Frelinger; Karin Przyklenk
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01-07       Impact factor: 8.311

5.  Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation.

Authors:  H Chang; I B Yanachkov; E J Dix; Y F Li; M R Barnard; G E Wright; A D Michelson; A L Frelinger
Journal:  J Thromb Haemost       Date:  2012-12       Impact factor: 5.824

6.  New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors.

Authors:  Ivan B Yanachkov; Hung Chang; Milka I Yanachkova; Edward J Dix; Michelle A Berny-Lang; Thomas Gremmel; Alan D Michelson; George E Wright; Andrew L Frelinger
Journal:  Eur J Med Chem       Date:  2015-11-09       Impact factor: 6.514

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.